MicroRNAs as novel biomarkers for rivaroxaban therapeutic drug monitoring.
atrial fibrillation
biomarker
miRNA
polymorphism
rivaroxaban
Journal
Drug metabolism and personalized therapy
ISSN: 2363-8915
Titre abrégé: Drug Metab Pers Ther
Pays: Germany
ID NLM: 101653409
Informations de publication
Date de publication:
13 08 2021
13 08 2021
Historique:
received:
29
10
2020
accepted:
06
07
2021
entrez:
6
4
2022
pubmed:
7
4
2022
medline:
9
4
2022
Statut:
epublish
Résumé
The aim of this study is to assess micro-RNAs miR-142 and miR-39 as potential biomarkers for drug-monitoring of rivaroxaban among elderly patients with atrial fibrillation. The study involved 57 patients with median (ME) age 87 years [80-94 years old] with nonvalvular atrial fibrillation admitted to a multidisciplinary hospital in Moscow. High-performance liquid chromatography with mass-spectrometry detection (HPLC-MS) was carried out to measure rivaroxaban concentrations. Carriership of The miR-142 expression levels of patients with CC allelic variant polymorphism This study has assessed new potential biomarkers for rivaroxaban therapeutic drug monitoring: miR-142 and miR-39.
Identifiants
pubmed: 35385896
pii: dmpt-2021-0118
doi: 10.1515/dmpt-2021-0118
doi:
Substances chimiques
Biomarkers
0
MicroRNAs
0
Rivaroxaban
9NDF7JZ4M3
Cytochrome P-450 CYP3A
EC 1.14.14.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-46Informations de copyright
© 2021 Walter de Gruyter GmbH, Berlin/Boston.
Références
Chugh, SS, Havmoeller, R, Narayanan, K, Singh, D, Rienstra, M, Benjamin, EJ, et al.. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 study. Circulation 2014;129:837–47. https://doi.org/10.1161/CIRCULATIONAHA.113.00511.
Kishore, A, Vail, A, Majid, A, Dawson, J, Lees, KR, Tyrrell, PJ, et al.. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke 2014;45:520–6. https://doi.org/10.1161/STROKEAHA.113.003433.
Ostroumova, OD, Cherniaeva, MS, Golovina, OV. Atrial fibrillation as risk factor for development of cognitive function impairment and dementia. Potential of anticoagulant therapy in their prevention. Kardiologiia 2018;58:76–88.
Steffel, J, Verhamme, P, Potpara, TS, Albaladejo, P, Antz, M, Desteghe, L, et al.. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018;20:1231–42. https://doi.org/10.1093/europace/euy054.
Gómez-Outes, A, Terleira-Fernández, AI, Lecumberri, R, Suárez-Gea, ML, Vargas-Castrillón, E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res 2014;134:774–82. https://doi.org/10.1016/j.thromres.2014.06.020.
Samuelson, BT, Cuker, A, Siegal, DM, Crowther, M, Garcia, DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017;151:127–38. https://doi.org/10.1016/j.chest.2016.08.1462.
Wieland, E, Shipkova, M. Pharmacokinetic and pharmacodynamic drug monitoring of direct-acting oral anticoagulants: where do we stand? Ther Drug Monit 2019;41:180–91. https://doi.org/10.1097/FTD.0000000000000594.
Sychev, DA, Baturina, OA, Mirzaev, KB, Rytkin, E, Ivashchenko, DV, Andreev, DA, et al.. CYP2C19*17 may increase the risk of death among patients with an acute coronary syndrome and non-valvular atrial fibrillation who receive clopidogrel and rivaroxaban. Pharmgenomics Pers Med 2020;13:29–37. https://doi.org/10.2147/PGPM.S234910.
Samama, MM, Contant, G, Spiro, TE, Perzborn, E, Le Flem, L, Guinet, C, et al.. Laboratory assessment of rivaroxaban: a review. Thromb J 2013;11:11. https://doi.org/10.1186/1477-9560-11-11.
Almegren, M. Reversal of direct oral anticoagulants. Vasc Health Risk Manag 2017;13:287–92. https://doi.org/10.2147/VHRM.S138890.
Reilly, PA, Lehr, T, Haertter, S, Connolly, SJ, Yusuf, S, Eikelboom, JW, et al.. RE-LY investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63:321–8. https://doi.org/10.1016/j.jacc.2013.07.104.
Testa, S, Paoletti, O, Legnani, C, Dellanoce, C, Antonucci, E, Cosmi, B, et al.. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemostasis 2018;16:842–8. https://doi.org/10.1111/jth.14001.
Seiffge, DJ, Traenka, C, Polymeris, A, Hert, L, Fisch, U, Peters, N, et al.. Feasibility of rapid measurement of Rivaroxaban plasma levels in patients with acute stroke. J Thromb Thrombolysis 2017;43:112–6. https://doi.org/10.1007/s11239-016-1431-7.
Cavallari, LH, Shin, J, Perera, MA. Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 2011;31:1192–207. https://doi.org/10.1592/phco.31.12.1192.
Tripodi, A, Ageno, W, Ciaccio, M, Legnani, C, Lippi, G, Manotti, C, et al.. Position paper on laboratory testing for patients on direct oral anticoagulants. A consensus document from the SISET, FCSA, SIBioC and SIPMeL. Blood Transfus 2018;16:462–70. https://doi.org/10.2450/2017.0124-17.
Sennesael, AL, Larock, AS, Douxfils, J, Elens, L, Stillemans, G, Wiesen, M, et al.. Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thromb J 2018;16:28. https://doi.org/10.1186/s12959-018-0183-3.
Rytkin, E, Mirzaev, KB, Bure, IV, Sychev, DA. Selection of miRNAs for clopidogrel resistance prediction. Meta Gene 2020;25. https://doi.org/10.1016/j.mgene.2020.100745.
Sharma, AR, Vohra, M, Shukla, V, Guddattu, V, Razak, UA, Shetty, R, et al.. Coding SNPs in hsa-miR-1343-3p and hsa-miR-6783-3p target sites of CYP2C19 modulates clopidogrel response in individuals with cardiovascular diseases. Life Sci 2020;245:117364. https://doi.org/10.1016/j.lfs.2020.117364.
Agarwal, V, Bell, GW, Nam, JW, Bartel, DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015;4:e05005. https://doi.org/10.7554/eLife.05005.
Rytkin, EI, Mirzaev, KB, Bure, IV, Sychev, DA. Micro-RNA as a new biomarker of activity of the cytochrome system P-450: significance for predicting the antiplatelet action of P2Y12 receptor inhibitors. Ter Arkh 2019;91:115–7. Russian. https://doi.org/10.26442/00403660.2019.08.000389.
Namino, F, Yamakuchi, M, Iriki, Y, Okui, H, Ichiki, H, Maenosono, R, et al.. Dynamics of soluble thrombomodulin and circulating miRNAs in patients with atrial fibrillation undergoing radiofrequency catheter ablation. Clin Appl Thromb Hemost 2019;25:1076029619851570. https://doi.org/10.1177/1076029619851570.
van den Berg, NWE, Kawasaki, M, Berger, WR, Neefs, J, Meulendijks, E, Tijsen, AJ, et al.. MicroRNAs in atrial fibrillation: from expression signatures to functional implications. Cardiovasc Drugs Ther 2017;31:345–65. https://doi.org/10.1007/s10557-017-6736-z.
Kiliszek, M, Maciak, K, Maciejak, A, Krzyżanowski, K, Wierzbowski, R, Gora, M, et al.. Serum microRNA in patients undergoing atrial fibrillation ablation. Sci Rep 2020;10:4424. https://doi.org/10.1038/s41598-020-61322-6.
Tang, QJ, Lin, HM, He, GD, Liu, JE, Wu, H, Li, XX, et al.. Plasma miR-142 accounting for the missing heritability of CYP3A4/5 functionality is associated with pharmacokinetics of clopidogrel. Pharmacogenomics 2016;17:1503–17. https://doi.org/10.2217/pgs-2016-0027.
Fulzele, S, Sahay, B, Yusufu, I, Lee, TJ, Sharma, A, Kolhe, R, et al.. COVID-19 virulence in aged patients might be impacted by the host cellular MicroRNAs abundance/profile. Aging Dis 2020;11:509–22. https://doi.org/10.14336/AD.2020.0428.